DekaBank Deutsche Girozentrale boosted its stake in shares of TESARO Inc (NASDAQ:TSRO) by 10.3% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 60,442 shares of the biopharmaceutical company’s stock after purchasing an additional 5,638 shares during the period. DekaBank Deutsche Girozentrale owned approximately 0.11% of TESARO worth $6,858,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Exane Derivatives acquired a new stake in TESARO during the 3rd quarter worth about $106,000. Botty Investors LLC purchased a new stake in shares of TESARO during the 2nd quarter worth about $140,000. Nordea Investment Management AB purchased a new stake in shares of TESARO during the 2nd quarter worth about $167,000. Oppenheimer Asset Management Inc. boosted its stake in shares of TESARO by 3,042.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 1,430 shares in the last quarter. Finally, Toronto Dominion Bank boosted its stake in shares of TESARO by 244.6% during the 3rd quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 1,130 shares in the last quarter.
Shares of TESARO Inc (NASDAQ TSRO) traded up $1.28 during midday trading on Monday, hitting $86.44. 855,033 shares of the stock were exchanged, compared to its average volume of 1,023,991. TESARO Inc has a fifty-two week low of $79.03 and a fifty-two week high of $192.94. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35.
TESARO (NASDAQ:TSRO) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The firm had revenue of $142.77 million during the quarter, compared to the consensus estimate of $130.57 million. During the same quarter last year, the firm earned ($1.72) EPS. The firm’s revenue for the quarter was up 740.3% on a year-over-year basis. sell-side analysts expect that TESARO Inc will post -8.16 EPS for the current fiscal year.
In other TESARO news, Director James O. Armitage sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $117.13, for a total value of $1,171,300.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $1,171,300. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Martin H. Jr. Huber sold 592 shares of the firm’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $118.60, for a total transaction of $70,211.20. Following the completion of the transaction, the senior vice president now directly owns 6,943 shares of the company’s stock, valued at approximately $823,439.80. The disclosure for this sale can be found here. Insiders sold a total of 21,525 shares of company stock valued at $2,716,431 in the last quarter. 34.60% of the stock is owned by insiders.
TSRO has been the topic of several recent analyst reports. SunTrust Banks reissued a “buy” rating and set a $235.00 target price on shares of TESARO in a research note on Sunday, August 20th. Citigroup reissued a “buy” rating and set a $216.00 target price on shares of TESARO in a research note on Monday, September 11th. Oppenheimer reaffirmed a “buy” rating and issued a $199.00 price target on shares of TESARO in a research note on Sunday, September 10th. Cann reaffirmed a “buy” rating and issued a $199.00 price target on shares of TESARO in a research note on Friday, September 8th. Finally, Credit Suisse Group set a $190.00 price target on shares of TESARO and gave the company a “buy” rating in a research note on Friday, August 18th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $159.39.
TRADEMARK VIOLATION WARNING: “TESARO Inc (NASDAQ:TSRO) Stake Raised by DekaBank Deutsche Girozentrale” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/12/04/tesaro-inc-tsro-shares-bought-by-dekabank-deutsche-girozentrale-2.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.